skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The race is on for companies to be among the first to CE mark their devices under the new EU regulations. Much will depend on which notified bodies are designated first; and national competent authorities play a key role.

 

Clues To Which Notified Bodies Will Be Designated First

 

 

Precise timing of application, and the quality of application dossiers are two key factors that will influence how quickly a notified body is designated under the EU's new Medical Devices and IVD Regulations.

 

 

According to a just-published Information note on joint assessments under the new regulations on medical devices from the European Commission, the day and the time of day the Commission receives the preliminary assessment report from the designating authority will be the main factor in deciding the order of the joint assessments –performed by the European Commission and representatives of two member states – and their allocation to any next available on-site assessment date.

 

 

The Commission has already been working on a tentative schedule of prospective on-site assessment dates to check the availability of both national and Commission experts. The intention is that future on-site assessments will then take place on those pre-established dates.

 

 

Another factor that may influence when notified bodies will be assessed by the joint assessment teams will be the availability of the team experts, the designating authority or the applicant conformity assessment body.

 

 

As an example, the Commission points to a situation where an application comes from a notified body that is established in a given EU member state, but one of the only two national experts available on the next on-site assessment date is from the same member state. In that case, the assessment will need to be rescheduled when two national experts from other member states are available, the Commission explains.

 

 

The Commission also stresses that it is of "utmost importance" that both the notified body’s application dossier and the designating authority’s preliminary assessment report are complete and properly address all the relevant legal requirements.

 

 

If any of these documents do not meet the requirements, it could cause a delay or a postponement in scheduling the on-site joint assessment to allow the conformity assessment body sufficient time to provide all the necessary clarifications and information.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。